Preventing a Mass Disease: The Case of Gallstones Disease. Role and Competence for Family Physicians

Ignazio grattagliano
Internal and general medicine, University of bari, Italy

*Corresponding author: Ignazio grattagliano, Internal and general medicine, University of bari, Italy, Tel: 0039-080-547823, Email: igratta@tin.it

Abstract
Gallstone formation is due to a complex interaction between genetic and nongenetic factors. Genes are estimated to account for only one-fourth of the overall gallstone risk, while metabolic/environmental factors are at least partially modifiable in stone-free risk groups, acting by primary prevention measures on diet, lifestyle and/or the environment or, in selected patients (i.e. rapid weight loss, bariatric surgery, somatostatin or analogues therapy, transient gallbladder stasis, hormone therapy). There is no specific recommendation for the secondary prevention of recurrent gallstones. Family physicians may contribute to achieve this specific goal, considering their capability of identifying and effectively managing several risk factors. Although further studies are needed to better explore the involvement of epigenetic factors regulating the effect of environment and lifestyle on gene expression in primary prevention of gallstone formation, preventive interventions are feasible and advisable in the general practice setting.

Keywords: Bile acids, Gallstones, Obesity, Primary prevention, Risk factors

Review Criteria
- GSD is one of the most frequent gastro-intestinal disorders in westernized countries.
- Due to the interplay of metabolic and lifestyle aspects in the pathogenesis of GSD, family physicians may play an important role in GSD prevention involving patients’ education.
- Exhaustive literature was selected and final selection was based on papers relevant for clinical practice.

Message for the Clinician
- The presence of gallstones should be checked regularly in at risk individuals.
- Consider systemic alterations in patients with cholesterol gallstones.
- Healthy lifestyle including diet, regular physical activity and maintenance of an ideal body weight, might prevent cholesterol GSD.
- Only obese patients on rapid weight loss and patients on long-term therapy with somatostatin or analogues might benefit from temporary therapy with UDCA as for primary prevention.

Introduction
Gallstone disease (GSD) is one of the most frequent gastrointestinal disorders in westernized countries [1-3], including Europe [4]. The 3 types of gallstones which develop in the gallbladder and bile ducts are distinguished by their chemical composition, and include cholesterol, pigment (black), and mixed (brown, containing small amounts of bilirubin salts and calcium). In industrialized countries 75% are cholesterol gallstones, about 20% are black and 5% are brown stones (Figure 1) [5-8]. Costs related to disease management are high due to diagnostic and surgical procedures involved [9]. Due to the interplay of metabolic and lifestyle aspects in the pathogenesis of GSD [2,10], family physicians (FPs) may play an important role in GSD prevention promoting appropriate patients’ education.

This paper focuses on the essential issues related to the prevention of GSD and is intended to provide FPs with few helpful evidences during everyday practice.

Search Methodology
Exhaustive literature in the period ranging from 1974 to 2015 was selected by accessing PubMed (http://www.ncbi.nlm.nih.gov/pubmed). Keywords included the terms bile acids, biliary stones, choledocolitiasis, gallbladder, gallstones, prevention, obesity, metabolic syndrome, bariatric surgery, very low-calorie diet, and ursodeoxycholic acid or cholesterol-lowering drugs. Prospective, retrospective cohort studies, case-controlled studies and metaanalyses published in English language in peer-reviewed international journals with impact factor were analyzed. Final selection was based on papers relevant for clinical practice.

Main Messages: The Essential Questions and the Answers
Who are the subjects at risk for and which are the most common modifiable factors in the prevention of GSD?

Several pathogenic mechanisms are identified for cholesterol GSD, namely genetic predisposition influencing cholesterol...
homeostasis (and possibly epigenetic changes), hepatic hypersecretion of cholesterol leading to supersaturated bile and accelerated precipitation of solid cholesterol crystals in a hypomotile gallbladder accommodating more mucins. Increased absorption of cholesterol from the intestine is another factor [2]. Although a positive family history suggests a role for genetic factors [11], genes are estimated to account for only about one-fourth of the overall gallstone risk, as suggested by the analysis of the Swedish twin registry [12]. In the majority of cases, a genetic background involving multiple pathways [13] determines an individual predisposition to develop cholesterol gallstones in response to a number of acquired unmodifiable and modifiable environmental factors (Table 1) [14]. As for other chronic metabolic diseases, also for GSD the gene-environment interactions and gene expression are possibly regulated by epigenetic mechanisms [14]. Approaches to preventive measures are especially effective in the case of cholesterol gallstones since modifiable pathogenic factors are often involved.

Obesity and metabolic factors: The main risk factors for cholesterol gallstone (e.g. obesity, type 2 diabetes, dyslipidemia, hyperinsulinemia) are components of the metabolic syndrome [2]. Increased body mass index is a risk factor for gallstone formation and growth [2], and acts as an independent risk factor for symptomatic GSD particularly in women [15]. Correlation also exists with waist circumference and triglyceridemia [16]. Additional obesity related pro-lithogenic factors might intervene, and include gallbladder stasis [17], insulin resistance, reduced HDL-cholesterol [16]. Appropriate lifestyle interventions might influence the pathogenesis of cholesterol gallstones and should focus on ideal weight maintenance and weight loss among overweight and obese individuals [15]. The key mechanisms regulating this pathogenic process seem to involve the gene-environment interaction through epigenetic mechanisms also occurring during the fetal age and involving lifestyle, toxic agents and environmental pollutants [18].

Physical activity: People should be aware of the importance of performing a regular daily physical activity, whenever possible [19]. The overall beneficial effect goes beyond the simple protection for gallstone formation [20]. In the Epic-Norfolk prospective cohort study, energy expenditure and cardio-respiratory fitness [21] were investigated by questionnaire in 25,639 volunteers (40-74 years). Subjects were monitored over 14 years. After 5 years, 135 cases of symptomatic gallstones (70% women, 69% uncomplicated) were observed. After 14 years, 290 cases of symptomatic gallstones (68% women, 54% complicated) were recorded. The highest level of physical activity was associated with a 70% decreased risk of symptomatic gallstones in both sexes, with a likely causal effect seen after 5 years. Hyperinsulinemia promotes hepatic uptake of cholesterol [22] with increased secretion in bile [23] and decreased secretion of bile acids [24] (leading to supersaturated lithogenic bile). The regular exercise reduces insulin levels [25], insulin resistance [26], triglyceridemia [27], fatty acid-dependent hypersecretion of gallbladder mucin [28], and increases serum HDL-cholesterol [29]. HDL-cholesterol is the precursor of bile acids [30] and is inversely related to gallstone prevalence [31]. Also, physical activity promotes a cholecystokinin-dependent gallbladder contraction [32].

Dietetic factors: Long-term population-based prospective studies have shown difficulties in estimating the quantity and ingestion pattern of nutrients. High-fiber and high-calcium diets reduce biliary hydrophobic bile acids while a regular eating pattern decreases gallbladder stasis by increasing its regular emptying [19]. Both aspects play a preventive role for GSD. The likelihood of GSD is increased by westernized diets including meat intake [33]. Fruit and
Table 1: Nongenetic risk factors for gallbladder stones including modifiable, potentially modifiable and non-modifiable factors.

<table>
<thead>
<tr>
<th>Factor</th>
<th>Pathogenic mechanism (s)</th>
<th>Stone Type</th>
<th>Intervention</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dietary</td>
<td>Westemized diet</td>
<td>Hepatic hypersecretion, associated metabolic factors, gallbladder stasis</td>
<td>Cholesterol</td>
</tr>
<tr>
<td></td>
<td>- high-calorie</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- low-fiber</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- high-refined carbohydrate</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- high-lipid</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lifestyles</td>
<td>Rapid weight loss (bariatric surgery of morbid obesity, very low calorie diet)</td>
<td>Hypersecretion of biliary mucin, hepatic hypersecretion, gallbladder stasis</td>
<td>Cholesterol</td>
</tr>
<tr>
<td></td>
<td>Physical inactivity (especially in men)</td>
<td>hepatic hypersecretion, intestinal and gallbladder hypomotility, decreased excretion of bile acids, increased serum triglycerides and insulin release</td>
<td>Cholesterol</td>
</tr>
<tr>
<td></td>
<td>Smoking</td>
<td>Metabolic factors? Others?</td>
<td>Cholesterol/Pigment</td>
</tr>
<tr>
<td></td>
<td>High Alcohol intake</td>
<td>Liver damage, reduced bile acid synthesis</td>
<td>Black pigment</td>
</tr>
<tr>
<td>Associated</td>
<td>Obesity</td>
<td>hepatic hypersecretion, gallbladder stasis</td>
<td>Cholesterol</td>
</tr>
<tr>
<td></td>
<td>Metabolic syndrome, Insulin resistance</td>
<td>Obesity, hepatic hypersecretion, dyslipidemia</td>
<td>Cholesterol</td>
</tr>
<tr>
<td></td>
<td>Hypertriglyceridemia</td>
<td>Association with other metabolic abnormalities, hepatic hypersecretion of cholesterol</td>
<td>Cholesterol</td>
</tr>
<tr>
<td></td>
<td>Micronutrients abnormalities: low serum magnesium</td>
<td>Insulin resistance and deranged serum LDL- and HDL-cholesterol</td>
<td>Cholesterol</td>
</tr>
<tr>
<td></td>
<td>Vitamin B-12/folic acid deficient diet</td>
<td>Hemolytic anemia</td>
<td>Black pigment</td>
</tr>
<tr>
<td></td>
<td>Pregnancy</td>
<td>Steroid hormones, gallbladder stasis, hepatic hypersecretion</td>
<td>Cholesterol</td>
</tr>
<tr>
<td></td>
<td>Gallbladder stasis (total parenteral nutrition, total gastrectomy with lymph node dissection, vagotomy, spinal cord injury, somatostatinoma, octreotide)</td>
<td>Increased bile concentration and precipitation/crystalization of cholesterol</td>
<td>Cholesterol</td>
</tr>
<tr>
<td></td>
<td>Estrogens and oral contraceptives.</td>
<td>Hepatic hypersecretion, gallbladder stasis</td>
<td>Cholesterol</td>
</tr>
<tr>
<td></td>
<td>Drugs: fibrates, octreotide, ceftriaxone, calcineurin inhibitors (tacrolimus, ciclosporin)</td>
<td>Precipitation in bile (ceftriaxone), hepatic hypersecretion, inhibition of hepatic bile salt export pump, bile concentration</td>
<td>Cholesterol</td>
</tr>
<tr>
<td></td>
<td>Diabetes mellitus*</td>
<td>Metabolic abnormalities, gallbladder stasis, autonomic neuropathy</td>
<td>Cholesterol</td>
</tr>
<tr>
<td>Others</td>
<td>Female gender</td>
<td>Pregnancies, steroid hormones, hepatic hypersecretion</td>
<td>Cholesterol</td>
</tr>
<tr>
<td></td>
<td>Increasing age</td>
<td>Metabolic risks, hemolytic anemia</td>
<td>Cholesterol, Pigment</td>
</tr>
<tr>
<td></td>
<td>Hemolytic anemia, sickle cell disease</td>
<td>Increased calcium bilirubinate concrements, gallbladder stasis</td>
<td>Black pigment</td>
</tr>
<tr>
<td></td>
<td>Liver cirrhosis</td>
<td>Gallbladder stasis, hyperestrogenism, bile salt malabsorption, increased enterohepatic circulation of bilirubin</td>
<td>Black pigment/Cholesterol</td>
</tr>
<tr>
<td></td>
<td>Cystic fibrosis</td>
<td>Increased biliary concentration of conjugated and unconjugated bilirubin and calcium, increased enterohepatic circulation of bilirubin</td>
<td>Black pigment</td>
</tr>
<tr>
<td></td>
<td>Crohn’s disease, extended ileal resection</td>
<td>Increased biliary concentration of conjugated and unconjugated bilirubin and calcium, increased enterohepatic circulation of bilirubin</td>
<td>Cholesterol/Black pigment</td>
</tr>
<tr>
<td></td>
<td>Infections (e.g. biliary strictures, duodenal diverticula, cholangitis, pancreatic insufficiency)</td>
<td>Bacterial β-glucuronization with biotransformation of conjugated to unconjugated bilirubin, precipitation together with calcium and long-chain fatty acids</td>
<td>Black pigment/brown pigment</td>
</tr>
</tbody>
</table>

*conditions especially associated with gallbladder stasis. Adapted from Portincasa et al. [2,49] with permission.

vegetables [34] might be protective, but data remains controversial. Unsaturated fats [35] might protect against GSD. Coffee is reported to be protective in some [36,37], but not all epidemiological studies [38]. Although prospective epidemiological studies reported protective effects of alcohol consumption on gallstone formation [16] and a Danish Mendelian randomization study indicated that patients with symptomatic gallstones consumed less alcohol as compared to those with asymptomatic stones [15], the findings are controversial [39] while alcohol cannot be recommended for prevention of gallstones. Vitamin C supplementation might have a protective effect. Cholesterol conversion to bile acids requires 7a-hydroxylation and an appropriate hepatocyte content of vitamin C [40]. Vitamin C deficiency might therefore increase the risk of cholesterol gallstone formation [41]. Vitamin C supplementation (500 mg x 4 times/day) changed biliary...
bile acid composition, increased phospholipids, and prolonged the cholesterol crystallization time [42]. Observational studies have identified an association between low vitamin C consumption and risk of GSD [41]. In the EMIL observational population-based study (n = 2129 subjects, 18-65 years), gallstone prevalence was 4.7% vs. 8.2% in patients reporting regular use of vitamin C (n = 232) or not (n = 1897), respectively [43].

Thus, based on current levels of evidence, a regular eating pattern with high-fiber and high calcium content, vitamin C supplementation and a preference for unsaturated fats should be suggested in subjects at risk for gallstone formation.

How to screen people at risk?

Abdominal ultrasonography is the most convenient first-line screening test because of non-invasiveness, low costs, simple procedure, and high sensitivity and specificity in detecting the presence of gallstones (84% and 99%, respectively) [44]. The same procedure allows a detailed and simultaneous study of gallbladder morphology (wall thickness, presence of polyps, sludge) and kinetics (fasting and postprandial gallbladder volume with estimation of half-emptying time in response to a standard fatty meal [2,17]. Compared to ultrasonography, computed tomography (CT) will not show gallstones if the concretion is isodense with bile [45]. CT with quantitative assessment of stone density may help to select patients for oral bile acid litholysis (i.e. presence of small [< 5 mm], uncalcified [radiotransparent] gallstones) [46]. For cholecodolithiasis, magnetic resonance cholangiopancreatography (MRCP) is the first choice approach, since it is noninvasive and has high sensitivity and specificity compared to ultrasonography [47]. Endoscopic ultrasonography (EUS) and endoscopic retrograde cholangiopancreatography (ERCP) have high sensitivity (80-90%) and specificity (100%) but are invasive [47], and both are not free of complications.

Is any form of pharmacological prevention of gallstones possible in the general population?

No rationale exists for using pharmacological therapy as prevention of GSD. Studies are mainly experimental or incomplete with lack of clinical meaning. Investigated agents include the bile acid ursodeoxycholic acid (UDCA), omega-3 fatty acids [48], statins [18], ezetimibe [18,49,50], spirin [51] or liver nuclear receptor regulators of cholesterol metabolism, i.e. FXR agonists [2].

Are there specific subgroups of subjects in which a primary prevention is feasible and sustainable?

Approach to primary and sometime secondary preventive measures are especially effective in the case of cholesterol gallstones (Figure 2).

Obese patients on rapid weight loss: If weight loss is rapid (i.e. over 1.5 kg/week) [52], the risk of gallstone formation, often asymptomatic, increases significantly. This is the case in patients starting very-low-calorie diets (i.e. < 800 kcal/day) [53] or bariatric surgery (up to 48% of patients for weight loss exceeding 25% of original weight) [53,54]. The overall risk decreases when body weight stabilizes, after approximately 24 months [53]. Weight cycling also represents an independent risk factor for gallstones [55]. Excessive de novo biosynthesis of cholestrol and biliary cholesterol excretion are the two main pathogenic factors [56]. Some preventive measures are possible during weight-reducing programs. It is advisable to keep the speed of weight loss to less than 1.5 kg/week.
The risk of developing symptomatic gallstones decreases if gallbladder motility is improved by appropriate fat content in diet (at least 7g/day) [53]. The litholytic hydrophobic UDCA greatly decreases the risk of cholesterol gallstone formation (< 10%) and that of becoming symptomatic [58] following rapid weight reduction [58,59]. A meta-analysis of five RCTs including 521 patients (322 on UDCA and 199 on placebo) concluded that UDCA 300-1, 200 mg/day effectively prevents gallstone formation after bariatric surgery [59] from 32% to 2% [60] with no severe side effects. The beneficial effect of (n-3) polyunsaturated fatty acids (11.3 g/day) on biliary cholesterol nucleation time and crystallization, and prevention of gallstone formation was confirmed in a randomized, double-blind placebo-UDCA (1,200 mg/day)-controlled trial in obese women [47]. The protective mechanism is probably mediated by replacement of biliary arachidonate by (n-3) PUFA [61], by increasing biliary phospholipids [62], change of intrahepatic cholesterol transport and hypersecretion of biliary cholesterol [63]. A concurrent prophylactic cholecystectomy has previously been recommended, based on the estimation that almost 19% of patients might require a cholecystectomy following bariatric surgery [64]. Data have not further supported since up to 97% of patients do remain asymptomatic, as confirmed by a recent decision analysis model [65].

**Patients on long-term therapy with somatostatin or analogues:** These patients exhibit biliary lithogenic changes and gastrointestinal motility changes, including delayed intestinal transit and gallbladder stasis [66,67]. Prophylactic therapy with UDCA has been suggested [67-69].

**Patients with marked gallbladder stasis:** Gallbladder stasis and changes of biliary composition are typical in pregnancy [70] or during prolonged fasting such as during total parenteral nutrition (TPN). Both sludge and small gallstones might disappear spontaneously in the postpartum period [70] and in TPN after restoration of oral diet [71]. Therefore there is no indication for oral litholysis in both conditions.

<table>
<thead>
<tr>
<th>Condition</th>
<th>Approach</th>
<th>Expected outcome(s)</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PRIMARY PREVENTION</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>General population</td>
<td>Healthy lifestyles&lt;br&gt;Weight loss of less than 1.5 Kg/week&lt;br&gt;Vitamin C consumption</td>
<td>Prevention, cure of concomitant metabolic disturbances&lt;br&gt;Decreased biliary saturation with cholesterol&lt;br&gt;Decreased propensity to cholesterol crystallization</td>
<td>e.g. dyslipidemia, overweight, obesity, insulin resistance, diabetes, etc.\</td>
</tr>
<tr>
<td>Obese patients on rapid weight loss - very low calorie diets - bariatric surgery</td>
<td>Oral UDCA (300-1, 200 mg/day)&lt;br&gt;Fish oil supplementation</td>
<td>Decreased biliary saturation with cholesterol&lt;br&gt;Increased biliary phospholipids (?)&lt;br&gt;Effect on intrahepatic cholesterol transport (?)</td>
<td>In particular during very low calorie diets. No effect on cholesterol saturation index [48].\</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Aspirin</td>
<td>Antiinflammatory effect</td>
<td>No indication</td>
</tr>
<tr>
<td></td>
<td>Prophylactic cholecystectomy (during Roux-en-Y gastric bypass)</td>
<td></td>
<td>Not routinely indicated</td>
</tr>
<tr>
<td>Patients on long-term therapy with somatostatin or analogues</td>
<td>Oral UDCA (300-1, 200 mg/day)</td>
<td>Decreased biliary saturation with cholesterol&lt;br&gt;Decreased propensity to cholesterol crystallization</td>
<td>Few prospective studies</td>
</tr>
<tr>
<td>Patients with marked transient gallbladder stasis</td>
<td>No indication for medical therapy</td>
<td>Spontaneous disappearance of sludge/small gallstones after restoration of physiological condition</td>
<td>Consider clinical follow-up</td>
</tr>
<tr>
<td>- Total parenteral nutrition</td>
<td>Oral UDCA (300-1, 200 mg/day)</td>
<td>Decreased biliary saturation with cholesterol&lt;br&gt;Decreased propensity to cholesterol crystallization</td>
<td>Controversial indication (spontaneous disappearance of gallstone/sludge after restoration of oral diet). Consider clinical follow up</td>
</tr>
<tr>
<td>- Pregnancy</td>
<td>Healthy lifestyles&lt;br&gt;Maintainance of nutritional requirement</td>
<td>Sludge, microstones can be transient&lt;br&gt;Spontaneous disappearance of gallstone/sludge in the postpartum period. Consider clinical follow up</td>
<td>Physicians who prescribe hormone replacement therapy should be aware of the increased risk for gallstones. Currently there is no indication for pharmacological or surgical stone prevention during hormone replacement therapy</td>
</tr>
<tr>
<td>Patients on hormone therapy</td>
<td>No indication</td>
<td>Lack of controlled trials</td>
<td></td>
</tr>
<tr>
<td><strong>SECONDARY PREVENTION</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Risk of recurrent gallstones</td>
<td>Oral UDCA (300-1, 200 mg/day)</td>
<td>Limitations: overall costs of chronic treatment and poor compliance. Advisable only in high risk subgroups (not fitting the criteria for subsequent cholecystectomy)</td>
<td>No specific recommendation can be given for the pharmacological prevention of recurrent gallstones</td>
</tr>
<tr>
<td>- Risk of recurrent bile duct stones</td>
<td></td>
<td></td>
<td>No specific recommendation can be given for the pharmacological prevention of recurrent gallstones</td>
</tr>
<tr>
<td>- Risk of recurrent gallstones, intrahepatic sludge and microolithiasis (low phospholipid-associated choledolithiasis)</td>
<td>Oral UDCA (300-1, 200 mg/day)</td>
<td>Prophylactic long term therapy with UDCA to be initiated as early as possible.</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: GSD: gallstone disease, UDCA: ursodeoxycholic acid
Patients on hormone therapy: A metaanalysis [72] showed a significantly increased risk of GSD in women under hormone replacement therapy for controlling menopausal symptoms or osteoporosis prevention [73]. The possibility of any pharmacological preventive approach has not been addressed, and has no rationale, thus far.

Is there any form of recommendation for the (secondary) prevention of recurrent gallstones?

Recurrent gallstones: Dissolution rate of cholesterol gallstones is 37-60% [74] after 2 years of treatment with UDCA. Recurrence is high following dissolution (15% by 1 year and 45% by 5 years) [75-77]. Pharmacological prophylaxis of gallstone recurrence could be restricted to very high risk subgroups or to patients not fitting the criteria of a subsequent cholecystectomy.

Recurrent biliary duct stones: There are no validated prophylactic measures for bile duct stones recurrence.

Patients with low phospholipid-associated cholelithiasis (LPAC): The heterozygous mutation of the gene ABCB4 encoding for the phospholipid-flippase is a rare form of monogenic predisposition for cholelithiasis associated with low biliary phospholipids and bile salt-mediated damage of the canalicular membrane. Before the age of 40, gallstones, intrahepatic sludge and microlithiasis develop, while biliary symptoms recur after cholecystectomy [78,79]. As suggested by few studies, the prophylactic long term therapy with UDCA should be initiated as early as possible [78,79].

Conclusions, Future Perspectives and Messages in General Practice

The epidemiology of GSD (including complications) and the costs for its management makes all possible efforts worth towards primary prevention strategies. In general practice, a key role should be that of identifying general and specific modifiable risk factor for GSD and those subgroups of subjects put at risk of GSD. In this setting, educational interventions aiming to prevent GSD should focus on healthy lifestyles, maintenance of ideal body weight, regular physical activity, prevention of metabolic syndrome, all factors influencing glyco-lipid metabolism and ultimately biliary cholesterol saturation. Pharmacological interventions are restricted to a subgroup of patients (Table 2). Further studies will need to address the involvement of epigenetic factors regulating gene expression in response to environmental factors, to identify even better preventive measures.

References


